Triangle Business Journal’s Post

💡 In Benchling's webinar, delve into the challenges of modern biopharma development. The speakers, Areef Jetha and Justin De La Cruz, PhD will guide you through overcoming hurdles in cell line development, upstream and downstream processing, and analytical operations for modern drug modalities. 📌 Watch the full webinar here: https://buff.ly/3tdircg #CellCulture #ProcessDevelopment #LaboratoryTechnology #CellLineDevelopment

Known for its abundant forests, smorgasbords, and, of course, the famed Europop group ABBA, Sweden has a thriving economy that largely depends on manufacturing and exports. Plus, the country’s life science sector recorded a net turnover of almost SEK 365 billion ($34 billion) in 2020 – an increase of just over SEK 158 billion ($14.8 billion) since 2014 – and it is still ever-growing. Labiotech.eu discusses eight #biotech companies in Sweden spearheading the country’s biotech scene. * Amferia * Anocca * Aprea Therapeutics * Asgard Therapeutics * BioInvent International AB * Diamyd Medical * Hamlet BioPharma * Modus Therapeutics Holding AB Find out more via https://lnkd.in/ew7FAXYQ

Recursion, a biotech firm which uses artificial intelligence to discover new drug candidates to acquire Exscientia, a technology-driven drug design and development company, for $688m. “We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high quality medicines and lower prices for consumers. Exscientia’s precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform, will augment our tech-enabled biology and chemistry exploration, hit discovery and translational capabilities. I am excited to continue building the best example of the next generation of biotechnology companies. It still feels like we are just getting started," Chris Gibson, Recursion Co-Founder and CEO. Exscientia (led by Dave H., Ben Taylor and Dan Ireland) is advised by Centerview Partners and A&O Shearman. Recursion (led by Chris Gibson, Michael Secora PhD and Nathan Hatfield) is advised by Allen & Company LLC. and Wilson Sonsini Goodrich & Rosati. #MergersAcquisitionsDivestitures #Pharmaceuticals #Biotechnology

Be sure to catch Wheeler's Chief Development Officer Brian R. Berquist, Ph.D. on ATUM's latest webinar where they will be taking a deep dive into many of the technologies, methods, and models that we utilize to ameliorate the translational gap in biologics development. #webinar #biologics #discovery

9 Steps to a Successful Lab Move. You’ve seen the signs. You’ve heard the whispers. Just like summer, a lab move is coming. Lab relocations are complex, but can be mastered with careful planning. By following nine main steps, it’s possible to ensure a successful lab move: https://hubs.li/Q02yFfb30 #labmove #science #biotech #pharma #research

Breaking down barriers to uncovering new drug candidates is essential for effective design and optimization of high-calibre therapeutics. Drug discovery relies heavily on expert input from diverse teams - from medicinal, synthetic, and computational chemists to biologists and drug metabolism and pharmacokinetics (DMPK) scientists. Providing specialist and unique insight, contract research organizations (CROs) can streamline the DMTA cycle and propel drug discovery processes forwards. David Bardsley and Nick Foster explore how CADD and cloud platforms help streamline drug discovery and facilitate communication, removing silos throughout the DMTA cycle, and helping organizations to make the molecules that matter.  https://obi41.nl/2p82z23u #DMTA #DrugDiscovery #DrugDesign #CADD

Our team of technical and business development experts is all geared up for the upcoming Drug Discovery Chemistry conference. This presents an opportunity to engage with them and gain insights into our cutting-edge drug discovery services designed to help you accelerate your drug discovery and development initiatives. Don't miss out—schedule a meeting now by clicking on the link: https://lnkd.in/gWn76RDW   At Aurigene, we specialize in the synthesis, optimization, and screening of drug candidates across various therapeutic areas. Our expertise extends to the synthesis and screening of specialized modalities such as PROTACs, peptides, steroids, PEGs, HPAPIs, and oligos, ensuring a comprehensive approach to addressing diverse research needs. For more information, write us at [email protected]. Rajeev Hotchandani Sangamesh Badiger Sreekar Reddy   #DrugDiscoveryChemistry #2024 #drugdiscovery #drugdevelopment #colloboration #innovation #synthesis #screening #optimization #crdmo #aurigene

SFBN Feed: AbbVie’s next CEO; $100B club refresh; Top 100 VCs, 2023; More hope for CAR-T in autoimmune; and more https://lnkd.in/gPjnb9tH Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

In the recent edition, Charting Excellence: Canada’s Top 5 Pioneers in Biotech, Insights Care is pleased to feature Starpax Biopharma, steered by its Founding President Michel Gareau, along with other biotech experts who made a difference Read More: https://bit.ly/4awDbwt #michaelgareau #StarpaxBiopharmaInc #cancertreatment #bestonlinehealthcaremagazine #healthcareinnovationmagazine

Patient-derived cells (PDCs): the future of drug discovery Drug discovery is known for its high attrition rates that lead to significant investments in both cost and time. However, the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development. In this blog, the Inaphaea team explores the potential of PDCs and their role in shaping the future of drug discovery. Read the blog here: https://bit.ly/43gvTcL #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #PDCs